Finnish
health technology company CurifyLabs has raised €12 million in a Series A
funding round to expand its operations in the United States and accelerate the
development of its platform for personalised medicine manufacturing. The round
was co-led by Sandwater and HealthCap, with participation from Tesi (Finnish
Industry Investment Ltd.), existing investor Lifeline Ventures, as well as
customers and employees in the United States.
Founded
in 2021, CurifyLabs develops technology for automated pharmaceutical
compounding. Its Compounding System Solution combines proprietary software,
GMP-manufactured excipient bases and three-dimensional printing technology to
automate the preparation of personalised medicines.
The platform is designed to
improve the consistency, precision and speed of compounding compared with
conventional manual pharmacy processes and includes integrated quality control
features.
CurifyLabs
said its technology is used by pharmacies in twenty-one US states and across
Europe to prepare personalised medications. As the company expands, it plans to
invest further in its supply chain to support its growing network of pharmacy
partners.
Commenting
on the company’s growth and future plans, Charlotta Topelius, founder and CEO
of CurifyLabs, said:
This
investment reflects the conviction our partners have in what we’re building. We
have set a high bar for clinical rigour, product quality and customer support,
and this funding gives us the resources to raise that bar further.
The
funding will be used to expand the company’s US operations, strengthen its
supply chain, enhance customer support and accelerate product development.
The
funding will also support continued development of the CurifyLabs platform,
including its latest product, the PharmaPrinter Aurum.